Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: insights from an EXenatide Study of Cardiovascular Event Lowering (EXSCEL) post-hoc analysis
Primary result · Incident bone fracturesResult — go to the resultHazard ratio 1.11 95 % CI 0.82–1.51Authors' conclusion
Bone fractures in people with T2D occur more frequently in those with diabetic neuropathy, but less frequently in those taking metformin. No evidence was seen of any impact of EQW treatment on bone fractures.
Study context
- Population
- People with T2D enrolled in EXSCELrandomised
- Participants
- 14,752 people
- Comparison
- Once-weekly exenatide 2 mg vs placebo; baseline predictors of fractures
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
Incident bone fractures
Hazard ratio
1.11
95 % CI 0.82–1.51
P = 0.49
EQWvs Placebo
HR 1.11 (95 % CI 0.82–1.51); P = 0.49
As reported in the abstract
- Primary outcome occurred (overall)
- 168 (1.1 %)
- Neuropathy at baseline: 50 % higher risk of fracture
- 1.50 (HR 1.50, 95 % CI 1.10-2.05, P = 0.010)
- Metformin at baseline: 47 % lower risk of fracture
- 0.53 (HR 0.53, 95 % CI 0.39-0.73, P < 0.001)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: insights from an EXSCEL post-hoc analysis. Diabetes Res Clin Pract. Published 26 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →